Loading company…
Nuevocor develops genetic medicines for genetic cardiomyopathies using its PrOSIA platform.
Founded in 2021 and based in Singapore, Nuevocor develops genetic medicines for genetic cardiomyopathies that currently lack treatment options. Its work draws on the PrOSIA mechanobiology platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in